BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.
about
Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5pInhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agentsTargeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond.Combined venetoclax and alvocidib in acute myeloid leukemia.Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
P2860
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
BET inhibition represses miR17 ...... ansformed hematopoietic cells.
@en
type
label
BET inhibition represses miR17 ...... ansformed hematopoietic cells.
@en
prefLabel
BET inhibition represses miR17 ...... ansformed hematopoietic cells.
@en
P2093
P2860
P50
P356
P1433
P1476
BET inhibition represses miR17 ...... ransformed hematopoietic cells
@en
P2093
S P Glaser
W S Alexander
P2860
P2888
P304
P356
10.1038/LEU.2016.52
P50
P577
2016-03-08T00:00:00Z
P6179
1016466301